Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction

The objective of this study was to understand the attitudes and preferences of risk‐eligible women regarding use of tamoxifen for breast cancer risk reduction.

[1]  J. Tobias.  Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Kuppermann,et al.  How do women of diverse backgrounds value prenatal testing outcomes? , 2004, Prenatal diagnosis.

[3]  M. Peruggia.  Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach (2nd ed.) , 2003 .

[4]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[5]  Sowmya R. Rao,et al.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.

[6]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[7]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[8]  E. Wooltorton.  Tamoxifen for breast cancer prevention: safety warning. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  A. Mulley,et al.  Making Good Decisions about Breast Cancer Chemoprevention , 2002, Annals of Internal Medicine.

[10]  U. P. S. T. Force,et al.  Chemoprevention of Breast Cancer: Recommendations and Rationale , 2002, Annals of Internal Medicine.

[11]  M. Wolfson,et al.  First do no harm: extending the debate on the provision of preventive tamoxifen , 2001, British Journal of Cancer.

[12]  E. Port,et al.  Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention , 2001, Annals of Surgical Oncology.

[13]  B. Rimer,et al.  Women's interest in chemoprevention for breast cancer. , 2001, Archives of internal medicine.

[14]  M. Levine,et al.  Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  Kaye,et al.  Re: tamoxifen prevention of breast cancer: an instance of the fingerpost , 2000, Journal of the National Cancer Institute.

[16]  B. Fisher.  Re: tamoxifen prevention of breast cancer: an instance of the fingerpost. , 2000, Journal of the National Cancer Institute.

[17]  P. Brown,et al.  Tamoxifen prevention of breast cancer: an instance of the fingerpost. , 1999, Journal of the National Cancer Institute.

[18]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[19]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[20]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[21]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[22]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[23]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[24]  Victor R. Fuchs,et al.  Economic Aspects of Health , 1983 .